Simcere Pharmaceutical Group Limited Share Price
Stocks
2096
HK0000658531
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
09:08:03 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 11.63 HKD | -1.19% |
|
+2.92% | -2.84% |
| 02:26am | Simcere Pharma's Yingmule Gets China Marketing Approval for RSV Prevention | MT |
| 09-03 | Hutchmed Enters Licensing Agreement With GSK for Cancer Drug | DJ |
| Market Cap | 3.86B 30.23B 3.32B 3.11B 2.85B 5.32B 364B 5.36B 36.83B 14.34B 186B 14.48B 14.16B 600B | P/E 2026 * |
14.7x | P/E 2027 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3.66B 28.68B 3.15B 2.95B 2.7B 5.04B 346B 5.08B 34.94B 13.61B 177B 13.74B 13.44B 569B | EV / Sales 2026 * |
2.44x | EV / Sales 2027 * | 2.2x |
| Free-Float |
32.13% | Yield 2026 * |
3.57% | Yield 2027 * | 4.06% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2096 | Delayed | |
OTC Markets
| SMHGF | Delayed | |
|
Deutsche Boerse AG
| S2P | Delayed | |
|
Tradegate
| S2P | Real-time | |
|
Börse Stuttgart
| S2P | Delayed | |
|
Boerse Muenchen
| S2P | Real-time |
| 1 day | -1.19% | ||
| 1 week | +2.92% | ||
| Current month | +4.77% | ||
| 1 month | -4.44% | ||
| 3 months | +20.52% | ||
| 6 months | +2.65% | ||
| Current year | -2.84% |
| 1 week | 10.96 |  | 12.01 |
| 1 month | 10.96 | | 12.82 |
| Current year | 9.07 | | 14.28 |
| 1 year | 9.07 | | 14.55 |
| 3 years | 4.94 | | 15.08 |
| 5 years | 4.94 | | 15.08 |
| 10 years | 4.94 | | 15.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CEO | Chief Executive Officer | 63 | 19/08/2026 |
Yunshu Zhou
CEO | Chief Executive Officer | 54 | 24/03/2026 |
Yushan Wan
DFI | Director of Finance/CFO | 55 | 18/11/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CHM | Chairman | 63 | 07/10/2012 |
Yushan Wan
BRD | Director/Board Member | 55 | 18/11/2019 |
Renhong Tang
BRD | Director/Board Member | 46 | 31/10/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/08/26 | Other | Chairperson | -3,000,000 | 0.1168% | ||
| 13/07/26 | Other | Founder | -47,000 | 0.0018% | ||
| 13/07/26 | Other | Director | -47,000 | 0.0018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.19% | +2.92% | -13.53% | +87.28% | 3.86B | |
| -0.89% | -1.09% | +20.02% | +71.25% | 48.63B | |
| -1.72% | -1.15% | +47.28% | +115.51% | 41.33B | |
| -2.01% | -5.96% | +10.68% | +80.50% | 12.06B | |
| -0.70% | -2.70% | -12.22% | +11.80% | 11.92B | |
| +0.57% | -0.56% | +26.56% | +153.11% | 9.15B | |
| -0.62% | -4.79% | +22.05% | +42.55% | 7.49B | |
| -0.89% | -3.09% | +22.42% | +220.05% | 7.34B | |
| -1.67% | -0.35% | +41.04% | -12.04% | 7.52B | |
| +0.03% | -2.72% | -42.28% | +14.39% | 5.19B | |
| Average | -0.91% | -0.68% | +12.20% | +78.44% | 15.45B | |
| Weighted average by Cap. | -1.10% | -0.36% | +22.79% | +84.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.5B 11.77B 1.29B 1.21B 1.11B 2.07B 142B 2.09B 14.34B 5.58B 72.52B 5.64B 5.51B 234B | 1.69B 13.27B 1.46B 1.37B 1.25B 2.33B 160B 2.35B 16.16B 6.29B 81.74B 6.35B 6.22B 263B |
| Net income | 255M 2B 220M 206M 189M 352M 24.13B 355M 2.44B 949M 12.33B 959M 938M 39.71B | 302M 2.37B 260M 244M 223M 416M 28.52B 419M 2.88B 1.12B 14.57B 1.13B 1.11B 46.94B |
| Net Debt | -197M -1.55B -170M -159M -146M -272M -18.65B -274M -1.88B -734M -9.53B -741M -725M -30.7B | -140M -1.1B -120M -113M -103M -193M -13.21B -194M -1.33B -520M -6.75B -525M -513M -21.74B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | HK$11.63 | -1.19% | 4,919,000 |
| 03/09/26 | HK$11.77 | -0.51% | 6,869,000 |
| 02/09/26 | HK$11.83 | +7.64% | 14,737,000 |
| 01/09/26 | HK$10.99 | -0.99% | 4,355,000 |
| 31/08/26 | HK$11.10 | -1.77% | 7,703,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2096 Stock
Select your edition
All financial news and data tailored to specific country editions
